The preliminary results of the Franco-Austrian biotech vaccine are encouraging, but the trial was conducted on a limited number of participants, in the laboratory and without comparison with other vaccines. The action rebounded for as much as more than 20% at the opening on Thursday.
Valneva’s anti-Covid vaccine generates neutralizing antibodies, there is a but… | Photo credits: (c) Sanofi Pasteur
Nearly 200 million euros in market capitalization went up in smoke in a single session. The title of biotech Valneva was battered on Wednesday, falling 12.04%, after the European Medicines Agency said it was awaiting additional data on its inactivated vaccine candidate VLA2001 against Covid-19. Valneva reacted quickly. In a statement released last night, the company says it has obtained encouraging data for the neutralization of the original strain and the Delta and Omicron variants. The news allows the title to regain color, since it rebounds by more than 20%, to 16.70 euros, after being reserved on the rise and having climbed by almost 30% in the first exchanges. But Valneva’s study has limitations. It was conducted on a limited number of 30 participants, in the laboratory and with a third injection of VLA2001 without comparison with the other vaccines.
Submission
Concretely, the laboratory technicians collected serum from the patients two and four weeks after they had received a booster dose of VLA2001, which was administered seven to eight months after the second dose of primary vaccination. ” All 30 samples (100%) showed neutralizing antibodies against the historical virus and the Delta variant, and 26 samples (87%) against the Omicron variant “, indicates the biotech. However, neutralization relative to the historical virus is reduced on average by 2.7 times for Delta and by 16.7 times for the Omicron variant.
” Studies carried out on a larger scale in vivo (tests carried out in humans and not in the laboratory) have shown that there was no correlation between the level of neutralizing antibodies against Omicron and the protection against infection by the virusunderlines the analyst of the firm Invest Securities in a note to its customers. A recent study in an Israeli hospital showed that a booster with the Pfizer or Moderna vaccines allowed an increase in the level of antibodies without, however, achieving effective protection against Omicron. Preliminary results therefore seemed to show that a fourth injection offered only partial defense against the virus. »
Pending additional studies, the biotech continues to submit registration dossiers to various health authorities in Europe, the United Kingdom and Bahrain. She hopes to be able to deliver her first doses in Europe in April.
PC